This is an aggregated industry headline. Read the full story at PharmaVoice →
Novo hikes guidance on Wegovy pill’s fast sales start
Sales and profit should shrink less than originally anticipated thanks to strong momentum for its new obesity pill, the drugmaker said in its most recent earnings report.
By PharmaVoice
· May 7, 2026
· via PharmaVoice
Image: PharmaVoice
Tags
moneyformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
MoneyFiercePharma ↗
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another ind…
MoneyFierceBiotech ↗
Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million…
MoneyFiercePharma ↗
Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to…